<DOC>
	<DOCNO>NCT01155947</DOCNO>
	<brief_summary>The purpose study compare bioavailability healthy , post menopausal woman subject fasting condition .</brief_summary>
	<brief_title>Bioavailability Study Anastrozole Tablets 1 mg Dr.Reddy 's Under Fasting Conditions</brief_title>
	<detailed_description>Open label , balance , randomize , two treatment , two-sequence , two period , crossover , single dose , comparative oral bioavailability study healthy , post menopausal woman subject fasting condition .</detailed_description>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>1 . The subject postmenopausal healthy woman attain complete menopause naturally surgically menstruation least one year hormone replacement therapy . 2 . The subject Estradiol level ≤ 20 pg/ml &amp; serum follicular stimulate hormone ( FSH ) level ≥ 50 mlU/ml screening . 3 . The subject screen within 21 day prior administration first dose study drug . 4 . The subject BMI 18.5 26.4 ( 3039 year ) , 18.5 27.8 ( 4049 year ) , 18.5 28.4 ( 5059 year ) &amp; 18.5 27.5 ( 6069 year ) weight kg/ height2 meter . 5 . The subject able communicate effectively study personnel . 6 . The subject able give write informed consent participate study . 1 . The subject history allergic response Anastrozole relate drug . 2 . The subject use female hormone replacement therapy , thyroid hormone replacement therapy , antihypertensive therapy . 3 . The subject significant disease clinically significant abnormal finding screen , ( medical history , physical examination , laboratory evaluation , ECG , Xray &amp; low abdominal ultrasonography recording ) . 4 . The subject disease condition might compromise haemopoeitic , gastrointestinal , renal , hepatic , cardiovascular , respiratory , central nervous system , diabetes , psychosis body system . 5 . The subject history presence bronchial asthma . 6 . The subject use enzymemodifying drug within 30 day prior receive first dose study medication . 7 . The subject history drug dependence , recent history alcoholism moderate alcohol use . 8 . The subject smoker , smoke equal 10 cigarette per day equal 20 biddy per day refrain smoke study period . 9 . The subject history difficulty donate blood difficulty accessibility vein . 10 . The subject donate ( 1 unit : 350 ml / 450 ml ) blood within 90 day prior receive first dose study medication . 11 . The subject positive hepatitis screen ( include subtypes A , B , C &amp; E ) . 12 . The subject positive test result Human Immunodeficiency Virus ( HIV ) antibody / syphilis Rapid Plasma Reagin , Venereal Disease Research Laboratory ( RPR/VDRL ) . 13 . The subject receive investigational product , participated drug research study within period 90 day prior first dose study medication administration .</criteria>
	<gender>Female</gender>
	<minimum_age>37 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Bioavailability</keyword>
	<keyword>Anastrozole</keyword>
	<keyword>Crossover</keyword>
</DOC>